The evaluation of RFA in unresectable advanced kidney cancer associated with the molecular target therapy as neo-adjuvant setting

The evaluation of RFA in unresectable advanced kidney cancer associated with the molecular target therapy as neo-adjuvant setting - Neo-RFA

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003748

Enrollment

Registered

2010-06-15

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

over T1b kidney cancer

Interventions

molecular target therapy,RFA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: kidney cancer T1b any LN any M 20years-80years male and female PS o or 1

Exclusion criteria

Exclusion criteria: 1) Heart pace maker 2) Difficult to insert the needle because of anatomical risk (artery, nerve, ureter) 3) Difficult to insert the needle because of anatomical risk (hilum, internal organ) 4) Difficult to calculate the tumor, malti focal tumor 5) Tendency of bleeding 6) Difficult to stop the medication to control coagulation or degradation of plate 7) Allergy to contrast medium 8) Complicated with infection 9) Active infection 10) Fever over 38 centigrade 11) Difficult to prolong the treatment for other focal therapy 12) Difficult to stop the chemotherapy and immunotherapy 13) The treatment history of the focal therapy to that location 14) Pregnancy 15) Justice to reject decided by main physician.

Design outcomes

Primary

Measure	Time frame
local progression free survival adverse event	—

Secondary

Measure	Time frame
progression free survival over all survival	—

Countries

Japan

Contacts

Public ContactNorihito Soga

Mie university urology

n-soga@clin.medic.mie-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026